Pangen Biotech Inc.
(주)팬젠
Verification summary
- Legal name (EN / KO)
- Pangen Biotech Inc. ((주)팬젠)
- Business registration no.
129-86-42227(1298642227)- Stock listing
- KOSDAQ listed · stock code
222110· DART00962922 - 12-month KONEPS contracts
1contract · KRW 1,189,500,000- Live NTS tax status
- Check live NTS status ↗
- verified_at
How to verify a Korean company (BRN format, live NTS status, DART & KONEPS) →
- English name (as registered with DART)
- Pangen Biotech Inc.
- Korean legal name
- (주)팬젠
- Alternate names
- 팬젠
- Market
KOSDAQ- Stock Code
222110- DART Corp Code
00962922- CEO
- 윤재승
- Business Registration No.
129-86-42227- Corporate Registration No.
1311110248194- Established Date
2010-01-29- Fiscal Month
12- KSIC Industry Code
212- Address (KO)
- 경기도 수원시 영통구 신원로 306, 2동 4층(원천동 영통이노플렉스)  
- Homepage
- https://www.pangen.com/ ↗
English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.
2026-11-01 04:28 UTCAnnual Financial Summary (KRW)
2025
Basis OFS (Separate)
Currency KRW
| Account | FY2025 (Current) | FY2024 (Prior) |
|---|---|---|
| Revenue (매출액) | KRW 13,416,632,780 | KRW 14,672,686,810 |
| Operating Income (영업이익) | KRW 1,506,235,749 | KRW 1,020,165,959 |
| Net Income (당기순이익) | KRW 2,050,626,610 | KRW 943,686,868 |
| Total Assets (자산총계) | KRW 32,700,285,210 | KRW 30,544,682,369 |
| Total Liabilities (부채총계) | KRW 2,776,156,154 | KRW 5,635,969,023 |
| Total Equity (자본총계) | KRW 29,924,129,056 | KRW 24,908,713,346 |
2026-11-08 02:22 UTCRecent DART Filings (Last 90 Days, up to 20)
| Filed | Theme | Filing (EN) | Filer |
|---|---|---|---|
| No filings in the last 90 days. | |||
Data from Korea's Financial Supervisory Service (OpenDART). FSS does not guarantee accuracy or completeness. Figures as filed, in the currency shown (usually KRW). Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.
2026-11-01 04:28 UTCPublic procurement (last 12 months)
Contracts first signed in the last 12 months.
The 12-month window is by original contract signing date: it covers contracts first signed in the period, and excludes amendments registered in the period to contracts signed earlier. Amounts are in KRW from Korea's Public Procurement Service (KONEPS). The 12-month total counts sole contracts in full and joint contracts by the supplier's share; joint contracts without a published share are counted but not summed. Multi-year contracts count only the current-period amount. Unit-price (framework) contracts are reported separately because their values are ceilings, not spend. Where KONEPS reports no total contract amount, the current-period amount is used as the total.
- Aggregation Period
2025-11-08to2026-11-07(basis:original_signed_date)- 12-Month Procurement Amount
- KRW 1,189,500,000
- 12-Month Contract Count
1(Joint contracts:1)- Unit-Price (Framework) Contracts (Reported Separately)
0contracts | Ceiling: KRW 0
By Procurement Category
| Category | Contracts | 12M Counted Amount (KRW) |
|---|---|---|
| Goods (물품) | 0 | KRW 0 |
| Construction (공사) | 0 | KRW 0 |
| Services (용역) | 1 | KRW 1,189,500,000 |
| Foreign Procurement (외자) | 0 | KRW 0 |
By Contract Type
| Contract Type | Contracts | Supplier Share / Current Amount (KRW) | Total Contract Ceiling / Multi-year Total (KRW) |
|---|---|---|---|
| Lump-sum / Standard (총액·일반) | 0 | KRW 0 | KRW 0 |
| Multi-year / Continuing (장기·계속비) | 1 | KRW 1,189,500,000 | KRW 3,900,000,000 |
| Unit-price / Framework Ceiling (단가·제3자단가 — excluded from 12M total) | 0 | KRW 0 | KRW 0 |
| Unclassified / Zero-amount (기타) | 0 | KRW 0 | KRW 0 |
Top 5 Government Buyers
| Buyer (Korean Legal Name) | Agency Code | Contracts | 12M Amount (KRW) |
|---|---|---|---|
| 질병관리청 국립보건연구원 | 1790399 | 1 | KRW 1,189,500,000 |
Recent Contracts (up to 1)
| Signed Date | Contract No. (KONEPS) | Contract Title (KO) | Category / Type | Buyer (KO) | Contract Amount (KRW) | Participation |
|---|---|---|---|---|---|---|
| 2026-06-22 | R26TA01978489 ↗ |
[학술/장기1차] 중증열성혈소판감소증후군(SFTS) 치료용 항체 비임상 시료 생산체계 고도화 및 평가 | services / multi_year |
질병관리청 국립보건연구원 | KRW 1,300,000,000 | Joint (91.5%) |